Fluidigm Corporation (FLDM) and Its Competitors Head to Head Comparison
Fluidigm Corporation (NASDAQ: FLDM) is one of 18 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it weigh in compared to its peers? We will compare Fluidigm Corporation to related companies based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, risk, dividends and profitability.
This is a summary of recent recommendations for Fluidigm Corporation and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Fluidigm Corporation Competitors||114||481||792||16||2.51|
Fluidigm Corporation presently has a consensus price target of $9.00, indicating a potential upside of 75.44%. As a group, “Medical Software & Technology Services” companies have a potential upside of 16.79%. Given Fluidigm Corporation’s stronger consensus rating and higher probable upside, equities analysts plainly believe Fluidigm Corporation is more favorable than its peers.
This table compares Fluidigm Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Fluidigm Corporation Competitors||-18.37%||-12.09%||-2.31%|
Insider & Institutional Ownership
88.9% of Fluidigm Corporation shares are owned by institutional investors. Comparatively, 63.1% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 4.7% of Fluidigm Corporation shares are owned by insiders. Comparatively, 21.9% of shares of all “Medical Software & Technology Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Fluidigm Corporation and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Fluidigm Corporation||$96.72 million||-$62.62 million||-2.09|
|Fluidigm Corporation Competitors||$376.98 million||$34.79 million||9.38|
Fluidigm Corporation’s peers have higher revenue and earnings than Fluidigm Corporation. Fluidigm Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Fluidigm Corporation has a beta of 3.36, suggesting that its stock price is 236% more volatile than the S&P 500. Comparatively, Fluidigm Corporation’s peers have a beta of 1.33, suggesting that their average stock price is 33% more volatile than the S&P 500.
Fluidigm Corporation peers beat Fluidigm Corporation on 7 of the 12 factors compared.
Fluidigm Corporation Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.